Lantheus Holdings, Inc. (LNTH) Q4 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning. Welcome to the Lantheus fourth quarter and full year 2024 conference call. All lines have been placed on mute. This call is being recorded and a replay will be available in the investor section of the company's website approximately two hours after the completion of the call. The call will be archived for at least 30 days. I'll now turn the call over to Mark Canarni, Vice President of Investor Relations. Mark? Thank you. Good morning. With me today are Brian Markison, our CEO, Paul Blanchfield, our President, Bob Marshall, our CFO, and Amanda Morgan, our Chief Commercial Officer. We will begin with prepared remarks and then open the call for Q&A. This morning we issued a press release which was furnished to the SEC under Form 8K reporting our fourth quarter 2024 results. The release and today's slide presentation are in the investor section of our website. Any comments made could include forward-looking statements. Actual results may differ materially from these statements due to a variety of risks and uncertainties which are detailed in our SEC filings. Discussions will also include certain non-GAAP financial measures. Reconciliation of these measures to the most directly comparable GAAP financial measures is included in the investor section of our website. I will now turn the call over to our CEO, Brian. Thank you, Mark, and good morning, everyone. 2024 was a groundbreaking year for Lantheus as we achieved a number of important milestones and enhanced our capabilities as the leading radiopharmaceutical focus company. I am immensely proud of our team and the meaningful difference we have made in the lives of over 7 million patients in 2024. Our strong performance in the fourth quarter and throughout all of 2024 was driven by our commitment to operation...